

Division of Healthcare Financing

Medicaid Pharmacy News

Dear Providers: December 20, 2013

NEW THERAPEUTIC CATEGORIES/PREFERRED DRUG LIST (PDL) CHANGES (Effective 01/01/2014)

Please refer to http://wymedicaid.org/ for the complete PDL.

THERAPEUTIC CATEGORY	PREFERRED MEDICATIONS/PDL CHANGES
ALLERGY/ASTHMA	Combivent, ipratropium, and Spiriva
Anticholinergic Bronchodilators	*Combivent will be preferred
ALLERGY/ASTHMA	Advair/HFA, Dulera, Symbicort
Corticosteroid/Bronchodilator Combinations	*Breo Ellipta will be non-preferred and will require a diagnosis of COPD and
	trial and failure of a preferred agent greater than or equal to 30 days
ALLERGY/ASTHMA	Astelin
Nasal Antihistamines	*Brand name Astelin will be preferred and generic azelastine will be non- preferred
ALLERGY/ASTHMA	Beconase AQ, flunisolide, fluticasone, and Nasonex
Nasal Steroids	*Beconase AQ and flunisolide will be preferred, Nasocort AQ will be non- preferred
ALLERGY/ASTHMA	Proair HFA, Proventil HFA, and Ventolin HFA
Short-acting Bronchodilators – Inhalers	*Ventolin HFA will be preferred
EPINEPHRINE	Epi-Pen
	*Epi-Pen will be preferred, Adrenaclick, Auvi-Q, and epinephrine will be
	non-preferred
ADDICTION AGENTS	Suboxone film and Zubsolv
Buprenorphine Combinations	* Zubsolv will be preferred (clinical criteria applies)
ANTIBIOTICS	Tobi
Inhaled Tobramycin	*Tobi will be preferred, Bethkis, Tobi Podhaler, and inhaled tobramycin will
	be non-preferred
ANTIDEPRESSANTS	*Brintellix will be non-preferred and require a trial and failure of two (2)
Other	preferred agents in any antidepressant class prior to approval
ANTIHYPERTENSIVES	Benicar, Diovan, irbesartan, and losartan
Angiotensin Receptor Blockers (ARBs)	*Generic irbesartan will be preferred, brand name Avapro will be non- preferred
ANTIHYPERTENSIVES	Benicar HCT, Diovan HCT, irbesartan HCTZ, and losartan HCTZ
ARBs and Diuretics	*Generic irbesartan HCTZ will be preferred, brand name Avalide will be non-
	preferred
ANTIVIRALS	*Aptivus, Crixivan, Invirase, Lexiva, Norvir <u>tablets</u> , Prezista, Reyataz, and
	Viracept will be preferred, Norvir <u>capsules</u> and <u>solution</u> will be non- preferred
CHOLESTEROL	*Niacor and Niaspan will be preferred
Niacin	
CHOLESTEROL	Caduet and Vytorin
Statin Combinations	*Liptruzet will be non-preferred

THERAPEUTIC CATEGORY	PREFERRED MEDICATIONS/PDL CHANGES
CONTRACEPTIVES	*Caziant, Femcon FE, and Loestrin 24 FE, 1/20-21, and 1/20 FE will be
	preferred, levonorgestrel/ethinyl estrad (91-Day) will be non-preferred
DIABETES	Lantus vial and Solostar
Long-acting Insulin	*Lantus Solostar will be preferred
DIABETES	*Humulin R and Novolin R will be preferred
Short-acting Insulin	·
EAR	Neo/Poly/HC solution and suspension and ofloxacin
Antibiotic/Steroid Combinations	*Neo/Poly/HC <u>solution</u> and <u>suspension</u> will be preferred, ciprofloxacin 0.2% will be non-preferred
GASTROINTESTINAL	Lansoprazole capsules, omeprazole capsules, pantoprazole
Proton Pump Inhibitors	*Lansoprazole capsules will be preferred, Achiphex sprinkles, lansoprazole
·	solutabs, and rabeprazole tablets will be non-preferred
GROWTH HORMONE	Genotropin, Humatrope, and Norditropin
	*Humatrope will be preferred (clinical criteria applies) and Nutropin AQ will
	be non-preferred
HEPATITIS C	Incivek and Victrelis
Protease Inhibitors	*Incivek will be preferred
IMMUNOMODULATORS	Enbrel, Humira, and Simponi
	*Simponi will be preferred (clinical criteria applies)
MULTIPLE SCLEROSIS	Avonex and Rebif
Interferon	*Rebif will be preferred
NSAIDS	*Zorvolex will be non-preferred
Combination Products	
OPTHALMICS	cromolyn, Optivar, Pataday, and Patanol
Anti-Allergics	*Brand name Optivar will be preferred and generic azelastine will be non- preferred
OPHTHALMICS	Combigan, dorzolamide/timolol, and Simbrinza
Combination Products	*Combigan and Simbrinza will be preferred
PHOSPHATE BINDERS	calcium acetate <i>capsules</i> , Eliphos, Phoslyra, and Renagel
	*Phoslyra will be preferred
PROGESTIN	*Makena will be preferred (clinical criteria applies)
PULMONARY ANTIHYPERTENSIVES	Letairis and Tracleer
Endothelin Receptor Antagonists	*Tracleer will be preferred (clinical criteria applies)
PULMONARY ANTIHYPERTENSIVES	Adempas
Soluble Guanylate Cyclase Stimulators	*Adempas will be preferred (clinical criteria applies)
AMPHETAMINES	Amphetamine salts combination XR, Dexedrine capsules, Vyvanse
Long Acting Amphetamines	*Brand name Dexedrine capsules will be preferred (clinical criteria applies)
	and generic dextroamphetamine CR capsules will be non-preferred
TOPICAL AGENTS	Lindane, Natroba, and permethrin solution
Scabicides/Pediculocides	*Lindane, Natroba and permethrin <u>solution</u> will be preferred, permethrin
	<u>cream</u> will be non-preferred

ADDITIONAL THERAPEUTIC CHART CHANGES

(Effective 01/01/2014)

Please refer to http://wymedicaid.org/ for the complete Additional Therapeutic Chart.

THERAPEUTIC CLASS	CLINICAL CRITERIA CHANGES
FYCOMPA	Client must have diagnosis of epilepsy in the last 12 months.
VALPROIC ACID, VALPROATE, DIVALPROEX	Client must have diagnosis of epilepsy, bipolar disorder, mood disorder,
	schizoaffective disorder, or migraine in the last 12 months.
XYREM	Client is required to have been diagnosed by a sleep specialist as having
	narcolepsy and must have completed a thirty day trial and failure of
	modafanil and methylphenidate or dextroamphetamine at the maximum
	recommended doses.

MAXIMUM DOSE LIMIT CHANGES

(Effective 01/01/2014)

Please refer to http://wymedicaid.org/ for the complete Dosage Limitation List.

PRODUCT	DAILY MAX DOSE
Brintellix	30mg

2014 PHARMACY PROVIDER MANUAL

The 2014 Pharmacy Provider Manual is now available for online viewing at www.wymedicaid.org. Please call the GHS Pharmacy Help Desk with any questions regarding the Pharmacy Provider Manual. If a provider would like a paper copy, the GHS Pharmacy Help Desk will mail a copy upon request.